Clearside Biomedical Inc (CLSD) Expected to Post Earnings of -$0.56 Per Share
Wall Street analysts expect Clearside Biomedical Inc (NASDAQ:CLSD) to post ($0.56) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Clearside Biomedical’s earnings. The highest EPS estimate is ($0.32) and the lowest is ($0.76). Clearside Biomedical posted earnings of ($0.65) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.8%. The firm is scheduled to issue its next earnings report on Wednesday, March 13th.
According to Zacks, analysts expect that Clearside Biomedical will report full year earnings of ($2.57) per share for the current fiscal year, with EPS estimates ranging from ($2.77) to ($2.33). For the next financial year, analysts expect that the firm will post earnings of ($1.31) per share, with EPS estimates ranging from ($1.50) to ($1.04). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Clearside Biomedical.
Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12).
NASDAQ:CLSD traded up $0.05 during trading on Thursday, reaching $1.41. The company’s stock had a trading volume of 177,400 shares, compared to its average volume of 532,895. The company has a market capitalization of $43.55 million, a PE ratio of -0.61 and a beta of -4.34. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.59 and a quick ratio of 4.59. Clearside Biomedical has a 12 month low of $1.31 and a 12 month high of $15.33.
Several hedge funds have recently bought and sold shares of CLSD. Kornitzer Capital Management Inc. KS grew its stake in shares of Clearside Biomedical by 23.7% during the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 92,800 shares of the company’s stock worth $992,000 after acquiring an additional 17,800 shares during the period. Alps Advisors Inc. bought a new position in shares of Clearside Biomedical during the 2nd quarter worth $496,000. Rhumbline Advisers grew its stake in shares of Clearside Biomedical by 43.2% during the 2nd quarter. Rhumbline Advisers now owns 26,703 shares of the company’s stock worth $285,000 after acquiring an additional 8,057 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Clearside Biomedical by 56.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 60,222 shares of the company’s stock worth $644,000 after acquiring an additional 21,622 shares during the period. Finally, GSA Capital Partners LLP bought a new position in shares of Clearside Biomedical during the 2nd quarter worth $534,000. Institutional investors own 57.94% of the company’s stock.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.
Featured Story: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.